Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

320 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhancement Of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma.
Nieto Y, Ramdial J, Valdez B, Thall PF, Bassett R, Barnett M, Srour S, Hosing C, Alousi A, Qazilbash M, Popat U, Gulbis A, Shigle TL, Ahmed S, Guillermo Pacheco M, Champlin R, Shpall EJ, Andersson BS. Nieto Y, et al. Among authors: qazilbash m. Clin Cancer Res. 2025 Jan 13. doi: 10.1158/1078-0432.CCR-24-3544. Online ahead of print. Clin Cancer Res. 2025. PMID: 39804167
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Nieto Y, et al. Among authors: qazilbash m. Cancer. 2016 Sep 1;122(17):2680-8. doi: 10.1002/cncr.30100. Epub 2016 May 20. Cancer. 2016. PMID: 27203405 Free PMC article.
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Veltri LW, et al. Cancer. 2017 Sep 15;123(18):3568-3575. doi: 10.1002/cncr.30770. Epub 2017 May 17. Cancer. 2017. PMID: 28513828 Free PMC article.
Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis.
Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Saini N, et al. Among authors: qazilbash mh. Clin Cancer Res. 2019 Nov 15;25(22):6781-6787. doi: 10.1158/1078-0432.CCR-19-0706. Epub 2019 Sep 3. Clin Cancer Res. 2019. PMID: 31481508
High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. Alkhaldi H, et al. Among authors: qazilbash m. Transplant Cell Ther. 2023 Nov;29(11):690-694. doi: 10.1016/j.jtct.2023.08.019. Epub 2023 Aug 20. Transplant Cell Ther. 2023. PMID: 37607645 Free article.
Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant.
Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y. Pasvolsky O, et al. Among authors: qazilbash m. BMC Cancer. 2023 Dec 20;23(1):1258. doi: 10.1186/s12885-023-11712-6. BMC Cancer. 2023. PMID: 38124057 Free PMC article.
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Qazilbash MH, et al. Biol Blood Marrow Transplant. 2008 Dec;14(12):1401-7. doi: 10.1016/j.bbmt.2008.09.019. Biol Blood Marrow Transplant. 2008. PMID: 19041063 Free PMC article. Clinical Trial.
Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies.
Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Kebriaei P, et al. Among authors: qazilbash m. Biol Blood Marrow Transplant. 2011 Mar;17(3):412-20. doi: 10.1016/j.bbmt.2010.07.016. Epub 2010 Jul 30. Biol Blood Marrow Transplant. 2011. PMID: 20674757 Free PMC article. Clinical Trial.
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. Nieto Y, et al. Among authors: qazilbash m. Biol Blood Marrow Transplant. 2012 Nov;18(11):1677-86. doi: 10.1016/j.bbmt.2012.05.011. Epub 2012 May 27. Biol Blood Marrow Transplant. 2012. PMID: 22643322 Free PMC article.
320 results